Nuvectis Pharma, Inc. NVCT
Institutional shares held
3.66 Million
97.7K
calls
0
puts
Total value of holdings
$22.1M
$588K
calls
$0
puts
Market Cap
$88.1M
14,642,500
Shares Out.
Institutional ownership
25.02%
# of Institutions
55
We take great care to ensure that the data presented and summarized in this overview for Nuvectis Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCT
View all-
Vanguard Group Inc Valley Forge, PA699KShares$4.21 Million0.0% of portfolio
-
Iridian Asset Management LLC586KShares$3.53 Million1.55% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Baldwin Brothers LLC390KShares$2.35 Million0.16% of portfolio
-
Geode Capital Management, LLC Boston, MA326KShares$1.96 Million0.0% of portfolio
-
Occam Crest Management LP Darien, CT290KShares$1.75 Million1.06% of portfolio
-
State Street Corp Boston, MA137KShares$823,0300.0% of portfolio
-
Northern Trust Corp Chicago, IL107KShares$641,9780.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA90.9KShares$547,0910.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$502,1400.0% of portfolio
Latest Institutional Activity in NVCT
Top Purchases
Top Sells
About NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Insider Transactions at NVCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2026
|
Michael J. Carson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
61,200
+23.42%
|
-
|
|
Jan 06
2026
|
Enrique Poradosu Chief Science & Business Off |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+7.67%
|
-
|
|
Jan 06
2026
|
Ron Bentsur Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+3.92%
|
-
|
|
Jan 06
2026
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+7.72%
|
-
|
|
Nov 05
2025
|
Matthew L. Kaplan Director |
BUY
Open market or private purchase
|
Direct |
11,000
+8.1%
|
$55,000
$5.84 P/Share
|
|
Nov 05
2025
|
Juan Sanchez Director |
BUY
Open market or private purchase
|
Direct |
13,000
+14.26%
|
$65,000
$5.79 P/Share
|
|
Nov 05
2025
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.14%
|
$25,000
$5.72 P/Share
|
|
Oct 27
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
72,836
+2.27%
|
$437,016
$6.28 P/Share
|
|
Oct 24
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
35,034
+1.13%
|
$210,204
$6.15 P/Share
|
|
Oct 23
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
46,900
+1.52%
|
$281,400
$6.06 P/Share
|
|
Sep 22
2025
|
Juan Sanchez Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+31.53%
|
-
|
|
Jun 20
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,603
+0.19%
|
$39,221
$7.99 P/Share
|
|
Jun 18
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
28,043
+0.93%
|
$224,344
$8.05 P/Share
|
|
Jun 17
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,399
+0.18%
|
$43,192
$8.11 P/Share
|
|
Jun 12
2025
|
Kenneth Hoberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+18.39%
|
-
|
|
Jun 12
2025
|
James F Oliviero Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.46%
|
-
|
|
Jun 12
2025
|
Matthew L. Kaplan Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.87%
|
-
|
|
May 12
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
21,167
+0.71%
|
$169,336
$8.11 P/Share
|
|
May 08
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,650
+0.02%
|
$21,200
$8.65 P/Share
|
|
May 07
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
12,317
+0.21%
|
$98,536
$8.52 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.14M
Shares
From
12
Insiders
| Grant, award, or other acquisition | 631K shares |
|---|---|
| Open market or private purchase | 511K shares |
Sell / Disposition
0
Shares
From
0
Insiders